People news: Incyte and Alliqua

Share this article:

Jim Daly left his post as head of North America commercial operations for Amgen to join biotech firm Incyte in the role of EVP and chief commercial officer. He arrives a year into the launch of Incyte's Jakafi, the first drug specifically approved for myelofibrosis, a rare, life-threatening blood cancer. Jakafi was also the first FDA-approved JAK inhibitor, a class that includes Pfizer's experimental rheumatoid arthritis pill tofacitinib.

James Sapirstein assumed the CEO position at Alliqua, a New York-based firm that produces and markets a transdermal drug delivery platform for wound care. A pharma veteran with more than 20 years of experience, Sapirstein has held several executive roles in the industry, most recently as CEO of privately held Tobira Therapeutics and as EVP at Serono Labs.  A pharmacist by training, he began his career as a sales rep at Roche. After a decade there, Sapirstein moved to Bristol-Myers Squibb, rising to director of international marketing for infectious diseases, then spent several years in global marketing at Gilead Sciences.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in People Moves

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in People Moves

Monday Moves: October 20

Promotions and hires for agencies and manufacturers

Monday Moves: September 29

Promotions and hires for agencies and manufacturers

Monday Moves—July 21, 2014

Hires and promotions for Manufacturers, Agencies and Media